1-20 of 201 Search Results for

ctla

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Current Directions in Autoimmunity
Volume: 5
Published: 19 December 2001
10.1159/000060550
EISBN: 978-3-318-00773-2
Book Chapter
Series: Chemical Immunology and Allergy
Volume: 59
Published: 23 August 1994
10.1159/000319246
EISBN: 978-3-318-01898-1
Book Chapter
Series: Chemical Immunology and Allergy
Volume: 59
Published: 23 August 1994
10.1159/000319247
EISBN: 978-3-318-01898-1
Book Chapter
Series: Chemical Immunology and Allergy
Volume: 59
Published: 23 August 1994
10.1159/000423689
EISBN: 978-3-318-01898-1
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437178
EISBN: 978-3-318-05590-0
... Abstract Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000436988
EISBN: 978-3-318-05590-0
... Abstract The development of new immunomodulatory monoclonal antibodies targeting the CTLA-4 or PD-1 axis has led to a revival of research on immunotherapies in solid tumours including renal cell cancer (RCC). The initial results observed with these monoclonal antibodies in the treatment...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437185
EISBN: 978-3-318-05590-0
... is a synergistic effect of different immune therapies like dendritic cell vaccination and CTLA-4 blockade with irradiation. Changes in the immune phenotype after radiotherapy can facilitate dendritic cell functioning. Immune therapy is also able to overcome the inhibitory pool of regulatory T cells through CTLA-4...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
EISBN: 978-3-318-05590-0
...References References 1. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al: A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987;328:267-270. 2. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al: Immunosuppression...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437186
EISBN: 978-3-318-05590-0
... than one immune system mechanism. As a prominent example, the simultaneous blockade of PD-1 and CTLA-4 is giving rise to therapeutic synergy, while still offering room for efficacy improvement. Moreover, combinations of immunomodulating agents with chemotherapy or targeted molecules are being tested...
Book Chapter
Series: Progress in Tumor Research
Volume: 44
Published: 07 May 2018
10.1159/000486981
EISBN: 978-3-318-06362-2
... for certain immune compartments are prone to tumour development and tumour growth [ 7 , 8 ]. Development of Ipilimumab One of the major advances of immunotherapy for cancer was achieved after studying basic mechanisms of T cell function [ 9 ]. CTLA-4 was discovered as an inhibitory molecule on T cells...
Book Chapter
Series: Progress in Tumor Research
Volume: 44
Published: 07 May 2018
EISBN: 978-3-318-06362-2
... NY Acad Sci 2013;1291:1-13. 10. Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465. 11. Tivol EA, et al: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 48
Published: 09 March 2017
10.1159/000452905
EISBN: 978-3-318-06014-0
...) forms, and the pathognomonic association of lymphocytic hypophysitis with pregnancy and CTLA-4 antibody therapy, have been clearly demonstrated. Meanwhile, non-invasive differential diagnosis remains extremely challenging since none of the suggested clinical, radiological or laboratory criteria...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 46
Published: 23 May 2016
10.1159/000443871
EISBN: 978-3-318-05840-6
... expression, cytotoxic T-lymphocyte antigen-4 (CTLA-4) , PTPN22 , STAT4, PD-L1, NALP1, FCRL3, GPR174, GATA3, NFATC1, CYP27B1 and the vitamin D receptor. In Western countries and Japan, an autoimmune process is responsible for the destruction of the adrenocortical cells and clinical manifestations...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000437183
EISBN: 978-3-318-05590-0
... or genetically engineered tumor-specific lymphocytes, therapeutic administration of monoclonal antibodies to target and eliminate tumor cells, and approaches that inhibit or destroy the molecular or cellular mediators of cancer-induced immunosuppression, such as CTLA-4, PD-1 or Treg cells. Here we provide...
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
EISBN: 978-3-318-05590-0
... cancer immunotherapy in mice. J Clin Invest 2010;120:1111-1124. 10. Peggs KS, Quezada SA, Chambers CA, et al: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206:1717-1725. 11. Waterhouse P...
Book Chapter
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
10.1159/000355903
EISBN: 978-3-318-02542-2
... and inhibitory signals that help regulate immune responses. Pharmacological inhibition of key immune checkpoints has proven to be one of the most successful strategies so far; inhibitory receptors like cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and PD-1 have been pioneered recently in the stage IV...
Book
Book Cover Image
Published: 06 November 2017
10.1159/isbn.978-1-910797-71-6
EISBN: 978-1-910797-71-6
Book Chapter
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/000436998
EISBN: 978-3-318-05590-0
... Coinhibitory Receptors The targets most advanced in development include cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1) and PD-1 ligand 1 (PD-L1; fig. 1 ). The anti-CTLA-4 agent ipilimumab was FDA-approved in 2011 for the treatment of metastatic melanoma based...
Book
Book Cover Image
Series: Progress in Tumor Research
Volume: 42
Published: 09 September 2015
10.1159/isbn.978-3-318-05590-0
EISBN: 978-3-318-05590-0
Book
Book Cover Image
Series: Current Directions in Autoimmunity
Volume: 5
Published: 19 December 2001
10.1159/isbn.978-3-318-00773-2
EISBN: 978-3-318-00773-2